AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00985868|
Recruitment Status : Active, not recruiting
First Posted : September 29, 2009
Last Update Posted : August 24, 2018
RATIONALE: AT9283 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of AT9283 in children and adolescents with relapsed and refractory solid tumors.
|Condition or disease||Intervention/treatment||Phase|
|Unspecified Childhood Solid Tumor, Protocol Specific||Drug: multikinase inhibitor AT9283 Other: enzyme-linked immunosorbent assay Other: immunohistochemistry staining method Other: laboratory biomarker analysis Other: pharmacological study||Phase 1|
- To evaluate the safety and tolerability of Aurora kinase inhibitor AT9283 by characterizing the dose-limiting toxicities in children and adolescents with relapsed and refractory solid tumors.
- To determine the maximum-tolerated dose of this regimen in these patients.
- To determine the pharmacokinetic parameters of this regimen in these patients.
- To demonstrate the pharmacodynamic (PD) activity of this regimen in these patients by studying its effects in surrogate tissue.
- To assess preliminary evidence of activity of this regimen by using appropriate objective tumor measurements in these patients.
- To demonstrate the PD activity of this regimen in these patients by studying its effects in both surrogate and tumor tissue (skin punch, bone marrow, and tumor biopsies).
OUTLINE: This is a multicenter, dose-escalation study.
Patients receive Aurora kinase inhibitor AT9283 IV over 72 hours on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.If a patient is benefiting from treatment with AT9283 (i.e. has stable or responding disease as measured by RECIST) and the benefit risk balance is considered acceptable then further treatment may be given.
Blood and skin tissue samples are collected at baseline and periodically during treatment for pharmacokinetic studies and pharmacodynamic and biomarker (M30, M65, pHH53, p53, PCNA and Ki67) analysis by IHC and ELISA assays.
After completion of study therapy, patients are followed up periodically.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||33 participants|
|Masking:||None (Open Label)|
|Official Title:||A CCLG/Cancer Research UK Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) Given for 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents With Relapsed and Refractory Solid Tumors|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||January 25, 2016|
|Estimated Study Completion Date :||December 2018|
- Dose-limiting toxicities
- Maximum-tolerated dose
- Pharmacokinetic parameters and the correlation between them and toxicity and/or efficacy
- The magnitude and duration of biomarkers (M30 and M65 ELISA) change after AT9283 administration
- Objective tumor response according to RECIST criteria
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00985868
|Birmingham Children's Hospital|
|Birmingham, England, United Kingdom, B4 6NH|
|Leeds General Infirmary|
|Leeds, England, United Kingdom, LS9 7TF|
|Royal Manchester Children's Hospital|
|Manchester, England, United Kingdom, M27 4HA|
|Great North Children's Hospital, Royal Victoria Infirmary|
|Newcastle-Upon-Tyne, England, United Kingdom, NE1 4LP|
|Royal Marsden - Surrey|
|Sutton, England, United Kingdom, SM2 5PT|
|Principal Investigator:||Darren Hargrave, MD||Great Ormond Street Hospital for Children NHS Foundation Trust|